Unicycive Therapeutics (NASDAQ: UNCY) net income
Unicycive Therapeutics reported a net loss of $26.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $36.7m. Earnings per share were −$1.67.
Unicycive Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$26.6m | — | — | −$1.67 |
| 2024 | −$36.7m | — | — | −$0.56 |
| 2023 | −$30.5m | — | −4,525.0% | −$1.28 |
| 2022 | −$18.1m | — | −1,898.8% | −$1.20 |
| 2021 | −$10.0m | — | — | −$0.86 |
| 2020 | −$2.3m | — | — | −$0.27 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Unicycive Therapeutics net income compared with its sector
By net income for its latest fiscal year, Unicycive Therapeutics ranks 220th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 218th | Travere Therapeutics | −$25.5m | −5.2% |
| 219th | Nuvectis Pharma | −$26.4m | — |
| 220th | Unicycive Therapeutics | −$26.6m | — |
| 221st | SELLAS Life Sciences Group | −$26.9m | — |
| 222nd | Weave Communications | −$28.1m | −11.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Unicycive Therapeutics
- How much did Unicycive Therapeutics earn in fiscal 2025?
- Unicycive Therapeutics reported a net loss of $26.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $36.7m.
- What are the earnings per share of Unicycive Therapeutics?
- They were −$1.67 in fiscal 2025, compared with −$0.56 in fiscal 2024.
- Where does Unicycive Therapeutics rank in its sector by net income?
- It ranks 220th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Unicycive Therapeutics come from?
- From the annual report (Form 10-K) that Unicycive Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Unicycive Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Unicycive Therapeutics: the Unicycive Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.